Literature DB >> 18537546

Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders.

F Rahimi1, A Shanmugam, G Bitan.   

Abstract

Several neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's and prion diseases, are characterized pathognomonically by the presence of intra- and/or extracellular lesions containing proteinaceous aggregates, and by extensive neuronal loss in selective brain regions. Related non-neuropathic systemic diseases, e.g., light-chain and senile systemic amyloidoses, and other organ-specific diseases, such as dialysis-related amyloidosis and type-2 diabetes mellitus, also are characterized by deposition of aberrantly folded, insoluble proteins. It is debated whether the hallmark pathologic lesions are causative. Substantial evidence suggests that these aggregates are the end state of aberrant protein folding whereas the actual culprits likely are transient, pre-fibrillar assemblies preceding the aggregates. In the context of neurodegenerative amyloidoses, the proteinaceous aggregates may eventuate as potentially neuroprotective sinks for the neurotoxic, oligomeric protein assemblies. The pre-fibrillar, oligomeric assemblies are believed to initiate the pathogenic mechanisms that lead to synaptic dysfunction, neuronal loss, and disease-specific regional brain atrophy. The amyloid beta-protein (Abeta), which is believed to cause Alzheimer's disease (AD), is considered an archetypal amyloidogenic protein. Intense studies have led to nominal, functional, and structural descriptions of oligomeric Abeta assemblies. However, the dynamic and metastable nature of Abeta oligomers renders their study difficult. Different results generated using different methodologies under different experimental settings further complicate this complex area of research and identification of the exact pathogenic assemblies in vivo seems daunting. Here we review structural, functional, and biological experiments used to produce and study pre-fibrillar Abeta assemblies, and highlight similar studies of proteins involved in related diseases. We discuss challenges that contemporary researchers are facing and future research prospects in this demanding yet highly important field.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537546      PMCID: PMC2835858          DOI: 10.2174/156720508784533358

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  262 in total

1.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry.

Authors:  E J Nettleton; P Tito; M Sunde; M Bouchard; C M Dobson; C V Robinson
Journal:  Biophys J       Date:  2000-08       Impact factor: 4.033

3.  Assembly of amyloid protofibrils via critical oligomers--a novel pathway of amyloid formation.

Authors:  A J Modler; K Gast; G Lutsch; G Damaschun
Journal:  J Mol Biol       Date:  2003-01-03       Impact factor: 5.469

4.  Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation.

Authors:  Chianping Ye; Dominic M Walsh; Dennis J Selkoe; Dean M Hartley
Journal:  Neurosci Lett       Date:  2004-08-19       Impact factor: 3.046

5.  High-resolution atomic force microscopy of soluble Abeta42 oligomers.

Authors:  Iris A Mastrangelo; Mahiuddin Ahmed; Takeshi Sato; Wei Liu; Chengpu Wang; Paul Hough; Steven O Smith
Journal:  J Mol Biol       Date:  2006-01-30       Impact factor: 5.469

6.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

7.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

Authors:  Stefan Barghorn; Volker Nimmrich; Andreas Striebinger; Carsten Krantz; Patrick Keller; Bodo Janson; Michael Bahr; Martin Schmidt; Robert S Bitner; John Harlan; Eve Barlow; Ulrich Ebert; Heinz Hillen
Journal:  J Neurochem       Date:  2005-08-31       Impact factor: 5.372

8.  Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes.

Authors:  Magdalena Anguiano; Richard J Nowak; Peter T Lansbury
Journal:  Biochemistry       Date:  2002-09-24       Impact factor: 3.162

Review 9.  Common mechanisms of amyloid oligomer pathogenesis in degenerative disease.

Authors:  Charles G Glabe
Journal:  Neurobiol Aging       Date:  2006-02-14       Impact factor: 4.673

10.  Cystatin C reduces the in vitro formation of soluble Abeta1-42 oligomers and protofibrils.

Authors:  M L Selenica; X Wang; L Ostergaard-Pedersen; A Westlind-Danielsson; A Grubb
Journal:  Scand J Clin Lab Invest       Date:  2007       Impact factor: 1.713

View more
  38 in total

Review 1.  Prion protein at the crossroads of physiology and disease.

Authors:  Emiliano Biasini; Jessie A Turnbaugh; Ursula Unterberger; David A Harris
Journal:  Trends Neurosci       Date:  2011-12-01       Impact factor: 13.837

2.  Aβ(39-42) modulates Aβ oligomerization but not fibril formation.

Authors:  Megan Murray Gessel; Chun Wu; Huiyuan Li; Gal Bitan; Joan-Emma Shea; Michael T Bowers
Journal:  Biochemistry       Date:  2011-12-23       Impact factor: 3.162

3.  Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.

Authors:  Farid Rahimi; Gal Bitan
Journal:  J Vis Exp       Date:  2010-05-13       Impact factor: 1.355

Review 4.  Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.

Authors:  Houshang Amiri; Kolsoum Saeidi; Parvin Borhani; Arash Manafirad; Mahdi Ghavami; Valerio Zerbi
Journal:  ACS Chem Neurosci       Date:  2013-09-26       Impact factor: 4.418

5.  A causative link between the structure of aberrant protein oligomers and their toxicity.

Authors:  Silvia Campioni; Benedetta Mannini; Mariagioia Zampagni; Anna Pensalfini; Claudia Parrini; Elisa Evangelisti; Annalisa Relini; Massimo Stefani; Christopher M Dobson; Cristina Cecchi; Fabrizio Chiti
Journal:  Nat Chem Biol       Date:  2010-01-10       Impact factor: 15.040

6.  Structural basis for Aβ1–42 toxicity inhibition by Aβ C-terminal fragments: discrete molecular dynamics study.

Authors:  B Urbanc; M Betnel; L Cruz; H Li; E A Fradinger; B H Monien; G Bitan
Journal:  J Mol Biol       Date:  2011-05-23       Impact factor: 5.469

Review 7.  Aβ oligomer-induced synapse degeneration in Alzheimer's disease.

Authors:  Kyle C Wilcox; Pascale N Lacor; Jason Pitt; William L Klein
Journal:  Cell Mol Neurobiol       Date:  2011-05-03       Impact factor: 5.046

8.  Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins.

Authors:  Sharmistha Sinha; Dahabada H J Lopes; Zhenming Du; Eric S Pang; Akila Shanmugam; Aleksey Lomakin; Peter Talbiersky; Annette Tennstaedt; Kirsten McDaniel; Reena Bakshi; Pei-Yi Kuo; Michael Ehrmann; George B Benedek; Joseph A Loo; Frank-Gerrit Klärner; Thomas Schrader; Chunyu Wang; Gal Bitan
Journal:  J Am Chem Soc       Date:  2011-09-29       Impact factor: 15.419

9.  Modulation of aggregate size- and shape-distributions of the amyloid-beta peptide by a designed beta-sheet breaker.

Authors:  Luitgard Nagel-Steger; Borries Demeler; Wolfgang Meyer-Zaika; Katrin Hochdörffer; Thomas Schrader; Dieter Willbold
Journal:  Eur Biophys J       Date:  2009-02-24       Impact factor: 1.733

10.  RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity.

Authors:  Farid Rahimi; Kazuma Murakami; Jamie L Summers; Chi-Hong B Chen; Gal Bitan
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.